Overweight and Obesity
Conditions
Interventions
Semaglutide treatment group:None
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. BMI>=24 kg/m^2 or waist circumference >=85 cm for men and >=80 cm for women 2. Age>=18 years, <=65 years. 3. No previous history of ASCVD (myocardial infarction, stroke, symptomatic peripheral arterial disease (claudication, gangrene)). 4. Treatment with semaglutide for at least 12 weeks during the enrollment period. 5. Signed informed consent must be obtained prior to enrollment in the study.
Exclusion criteria
Exclusion criteria: 1. life expectancy of less than 1 year during chemotherapy for severe liver disease (Child-Pugh class C) or malignant tumours or in combination with severe illnesses 2. participation in other interventional studies during the study period 3. treatment with simepaglutide within 2 years prior to screening; treatment with other GLP-1RA analogues within 3 months prior to screening or during enrolment 4. diagnosis of ASCVD prior to screening 5. participation in this study may, in the judgement of the investigator (or representative), expose the subject to significant risks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ASCVD risk categories; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative Incidence of Composite Cardiovascular Events; | — |
Countries
China
Contacts
Public ContactShen Can
West China Hospital of Sichuan University
Outcome results
None listed